Acquiring evidence for precision prostate cancer care

Por Mateo, J., Carreira, S., de Bono, J. S.
Publicado no Ann Oncol (2017)

Long term follow up of patients with repaired aortic coarctations

Por de Bono, J P, Freeman, L J
Publicado em 2005

Targeting IGF-1R: throwing out the baby with the bathwater?

Por Basu, B, Olmos, D, de Bono, J S
Publicado em 2011

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

Por Ang, J E, Olmos, D, de Bono, J S
Publicado em 2009

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

Por Stewart, A., Thavasu, P., de Bono, J. S., Banerji, U.
Publicado no Ann Oncol (2015)

Clinical anticancer drug development: targeting the cyclin-dependent kinases

Por Benson, C, Kaye, S, Workman, P, Garrett, M, Walton, M, de Bono, J
Publicado em 2005

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

Por Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S
Publicado em 2008

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

Por Attard, G, Sarker, D, Reid, A, Molife, R, Parker, C, de Bono, J S
Publicado em 2006

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience

Por Olmos, D, Arkenau, H-T, Ang, J E, de Bono, J S, Judson, I, Kaye, S B
Publicado em 2008

Drugs and the exercise test.

Por Muir, K. W., Rodger, J. C., DeBono, J. S., McDonald, H., Irving, J. B.
Publicado em 1992

The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

Por Kumar, R, Geuna, E, Michalarea, V, Guardascione, M, Naumann, U, Lorente, D, Kaye, S B, de Bono, J S
Publicado no Br J Cancer (2015)

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

Por Wilbaux, M, Tod, M, De Bono, J, Lorente, D, Mateo, J, Freyer, G, You, B, Hénin, E
Publicado no CPT Pharmacometrics Syst Pharmacol (2015)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado em 2009

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

Por Brunetto, A T, Sarker, D, Papadatos-Pastos, D, Fehrmann, R, Kaye, S B, Johnston, S, Allen, M, De Bono, J S, Swanton, C
Publicado em 2010

Telemetric analysis of haemodynamic regulation during voluntary exercise training in mouse models

Por Adlam, D., De Bono, J. P., Danson, E. J., Zhang, M. H., Casadei, B., Paterson, D. J., Channon, K. M.
Publicado no Exp Physiol (2011)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Por Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O.
Publicado em 2013

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

Por Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S
Publicado em 2014

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

Por Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Publicado em 2007

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Por Goodman, O B, Flaig, T W, Molina, A, Mulders, P F A, Fizazi, K, Suttmann, H, Li, J, Kheoh, T, de Bono, J S, Scher, H I
Publicado em 2014

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Por Mateo, J., Berlin, J., de Bono, J. S., Cohen, R. B., Keedy, V., Mugundu, G., Zhang, Lianglin, Abbattista, A., Davis, C., Gallo Stampino, C., Borghaei, H.
Publicado em 2014